Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$8.40 USD

8.40
310,518

-0.27 (-3.11%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $8.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Is AngioDynamics (ANGO) Up 8.7% Since Last Earnings Report?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio

by Zacks Equity Research

Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.

Zacks Equity Research

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Cardinal Health's (CAH) fiscal second-quarter results reflect strong segmental performance.

Zacks Equity Research

Zacks.com featured highlights include: AngioDynamics, ICICI Bank, LG Display Co and Mayville Engineering

by Zacks Equity Research

Zacks.com featured highlights include: AngioDynamics, ICICI Bank, LG Display Co and Mayville Engineering

Zacks Equity Research

Becton Dickinson (BDX) Earnings Surpass Estimates in Q1

by Zacks Equity Research

Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.

Zacks Equity Research

Quest Diagnostics (DGX) Q4 Earnings Top, Base Recovery Slows

by Zacks Equity Research

Quest Diagnostics' (DGX) first-half 2021 outlook looks impressive thanks to strong revenue growth expectations.

Zacks Equity Research

Change Healthcare (CHNG) Q3 Earnings Top Estimates, Up Y/Y

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance in the Network Solutions segment.

Zacks Equity Research

Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results reflect robust performance across five of its business units.

Zacks Equity Research

AmerisourceBergen (ABC) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.

Nitish Marwah headshot

Grab These 4 Breakout Stocks for Spectacular Gains

by Nitish Marwah

In case a stock falls below the lower bound of this band, it may be time to offload it from your portfolio.

Zacks Equity Research

Phibro (PAHC) Q2 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Phibro's (PAHC) second-quarter revenue declined 3.7% year over year to $206.1 million and gross profit improved 33%.

Zacks Equity Research

Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline

by Zacks Equity Research

Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.

Zacks Equity Research

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q3

by Zacks Equity Research

STERIS' (STE) third-quarter fiscal 2021 results reflect strong performance by all three of its reporting segments despite the coronavirus-led economic crisis.

Zacks Equity Research

PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) fourth-quarter results benefit from strong segmental performance.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts

by Zacks Equity Research

Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.

Zacks Equity Research

IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise

by Zacks Equity Research

IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.

Zacks Equity Research

McKesson (MCK) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

McKesson's (MCK) fiscal third-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.

Zacks Equity Research

Why You Should Add AngioDynamics (ANGO) to Your Portfolio

by Zacks Equity Research

Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.

Zacks Equity Research

Onmicell (OMCL) Q4 Earnings Beat Estimates, Margin Contracts

by Zacks Equity Research

Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.

Zacks Equity Research

AngioDynamics' (ANGO) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in AngioDynamics (ANGO).

Zacks Equity Research

What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

AngioDynamics (ANGO) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

AngioDynamics (ANGO) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.

Zacks Equity Research

AngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 150.00% and 8.01%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter performance is likely to reflect better performance by CVI and CSI.